苑东生物(688513) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥314,990,089.28, representing a year-on-year increase of 13.37%[3] - The net profit attributable to shareholders for the same period was ¥75,010,084.96, reflecting a growth of 23.00% compared to the previous year[3] - Operating profit for Q1 2024 was ¥80,220,974.65, up 17.5% from ¥68,278,212.94 in Q1 2023[19] - Net profit for Q1 2024 was ¥75,010,084.96, representing a 22.1% increase from ¥60,985,871.41 in Q1 2023[19] - Earnings per share for Q1 2024 were ¥0.63, compared to ¥0.51 in Q1 2023, reflecting a growth of 23.5%[20] - The total operating costs for Q1 2024 were ¥258,240,843.28, an increase of 14.0% from ¥226,451,481.30 in Q1 2023[18] Cash Flow - The net cash flow from operating activities increased significantly by 118.29%, amounting to ¥71,892,080.50[3][8] - Cash flow from operating activities for Q1 2024 was ¥71,892,080.50, significantly higher than ¥32,933,694.58 in Q1 2023[22] - The net cash flow from financing activities was -$63,998,569.10, indicating a significant outflow compared to the previous period's inflow of $49,320,319.44[23] - Total cash and cash equivalents at the end of the period amounted to $816,632,829.91, an increase from $767,540,657.11 at the beginning of the period[23] - Cash outflows from financing activities totaled $113,998,569.10, which included $60,000,000.00 for debt repayment and $1,281,279.84 for dividend payments[23] - The impact of exchange rate fluctuations on cash and cash equivalents was a decrease of $97,939.72[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,374,370,944.83, showing a slight increase of 0.83% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 3,374,370,944.83, an increase from RMB 3,346,754,293.88 as of December 31, 2023, reflecting a growth of approximately 0.82%[16] - Total current liabilities were RMB 666,671,871.78, slightly up from RMB 661,094,015.47, showing an increase of approximately 0.87%[16] - The total liabilities amounted to RMB 748,260,937.50, up from RMB 743,334,130.15, indicating an increase of about 0.81%[16] - Non-current assets totaled RMB 1,470,683,597.65, a slight increase from RMB 1,463,883,064.24, reflecting a growth of approximately 0.14%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,619[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] Research and Development - Research and development expenses totaled ¥63,140,560.59, which is 20.05% of the operating revenue, an increase of 1.57 percentage points year-on-year[4] - Research and development expenses for Q1 2024 totaled ¥54,184,914.96, an increase from ¥50,088,561.76 in Q1 2023[19] Other Information - The company reported non-recurring gains of ¥22,918,205.83 for the quarter[7] - The weighted average return on equity was 2.87%, an increase of 0.41 percentage points compared to the previous year[3] - The total equity attributable to shareholders was ¥2,626,110,007.33, up by 0.87% from the previous year-end[4] - The company reported a total equity attributable to shareholders of ¥2,626,110,007.33, up from ¥2,603,420,163.73 in Q1 2023[17] - There were no new strategies or product developments mentioned in the conference call[13] - The company did not apply new accounting standards or interpretations for the first quarter of 2024[23]